Neuronetics Stock Forum

$Neuronetics(STIM.US)$
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Neuronetics announced its participation in the 12th Annual Clinical TMS Society (CTMSS) Meeting in London from June 13-15, 2024. They will present six posters and one oral presentation showcasing data from the NeuroStar TMS System. Highlights include early prediction of nonresponse in major depressive disorder, the impact of treatment timing, efficacy of accelerated TMS protocols, effect...

$Neuronetics(STIM.US)$ Neuronetics Announced That Humana Has Become The First Commercial Payer To Address TMS Therapy Coverage For Adolescents

$Neuronetics(STIM.US)$
NEWS
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-...

$Neuronetics(STIM.US)$ NeuroStar Advanced Therapy Receives FDA Clearance As First-Line Add-On Treatment For Adolescents With Depression

$Neuronetics(STIM.US)$ Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
Dow Jones· just

$Neuronetics(STIM.US)$ Are there any upcoming developments or FDA approvals expected to come up in the near future ?

$Neuronetics(STIM.US)$ on move 👀

$Neuronetics(STIM.US)$ reported record revenue of $17.9 million for Q3 2023, marking an 8% increase from the same period last year. The company also revised its full-year revenue guidance to between $70 million and $72 million.